Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer

Reshma Mahtani, Miami Cancer Institute

Abstract

This paper has been withdrawn.